444 related articles for article (PubMed ID: 26917606)
1. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.
Barnes NC; Sharma R; Lettis S; Calverley PM
Eur Respir J; 2016 May; 47(5):1374-82. PubMed ID: 26917606
[TBL] [Abstract][Full Text] [Related]
2. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD.
Mathioudakis AG; Bikov A; Foden P; Lahousse L; Brusselle G; Singh D; Vestbo J
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32108044
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
[TBL] [Abstract][Full Text] [Related]
5. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
[TBL] [Abstract][Full Text] [Related]
7. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
Pavord ID; Lettis S; Anzueto A; Barnes N
Lancet Respir Med; 2016 Sep; 4(9):731-741. PubMed ID: 27460163
[TBL] [Abstract][Full Text] [Related]
8. Inhaled corticosteroids, blood eosinophils, and FEV
Whittaker HR; Müllerova H; Jarvis D; Barnes NC; Jones PW; Compton CH; Kiddle SJ; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():1063-1073. PubMed ID: 31213788
[No Abstract] [Full Text] [Related]
9. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis.
Hinds DR; DiSantostefano RL; Le HV; Pascoe S
BMJ Open; 2016 Jun; 6(6):e010099. PubMed ID: 27251682
[TBL] [Abstract][Full Text] [Related]
10. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids.
Kunz LI; Ten Hacken NH; Lapperre TS; Timens W; Kerstjens HA; van Schadewijk A; Vonk JM; Sont JK; Snoeck-Stroband JB; Postma DS; Sterk PJ; Hiemstra PS;
Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049170
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
12. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.
Pavord ID; Lettis S; Locantore N; Pascoe S; Jones PW; Wedzicha JA; Barnes NC
Thorax; 2016 Feb; 71(2):118-25. PubMed ID: 26585525
[TBL] [Abstract][Full Text] [Related]
13. Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD.
Cheng SL; Wang HH; Lin CH
Int J Chron Obstruct Pulmon Dis; 2017; 12():2231-2238. PubMed ID: 28814851
[TBL] [Abstract][Full Text] [Related]
14. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
15. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
[TBL] [Abstract][Full Text] [Related]
16. Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
Burge S
Drugs; 2001; 61(11):1535-44. PubMed ID: 11577791
[TBL] [Abstract][Full Text] [Related]
17. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.
Cheng SL
Int J Chron Obstruct Pulmon Dis; 2018; 13():2775-2784. PubMed ID: 30233168
[TBL] [Abstract][Full Text] [Related]
18. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
19. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.
Low EV; Hughes SM; Zaffarullah S; Kantas D; Stockley RA; Turner AM
Respiration; 2018; 95(2):114-121. PubMed ID: 29253843
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of inhaled fluticasone propionate in moderate to severe COPD.
Thompson WH; Carvalho P; Souza JP; Charan NB
Lung; 2002; 180(4):191-201. PubMed ID: 12391509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
